Table 1 Late deaths (> 5 years) in 5-year survivors of childhood solid tumour (N = 3,650, diagnosis period: 1973–2008, Hungarian Childhood Cancer Registry), time period of death, absolute and relative distribution of causes of death in main diagnostic groups.
From: Late mortality in survivors of childhood cancer in Hungary
Survivors > 5 yrs | Death | Time period | Causes of death: | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Number: (median FUP time) | Number and ratio % | Death during 5–10 yrs FUP | PROGR DIS−/ + complications | Progr dis and infection | Infection | Toxic event Transpl-related | Cardiovascular | Secondary cancer | Neurol. disease | Other internal disease | External | Unknown | |
Non-Hodgkin lymphoma | 367 (14.4) | 11 3% | 7 64% | 3 27% | 2 18% | 1 9% | 1 9% | – | 1 9% | – | 2 18% | – | 1 9% |
Hodgkin disease | 473 (15.9) | 49 10% | 19 39% | 14 (29%) 1 (2%) | 4 8% | 2 4% | 2 (4%) 1 (2%) | 10 20% | 8 16% | – | – | 2 4% | 5 10% |
Astrocytoma | 529 (15.7) | 41 8% | 18 44% | 27 66% | – | 4 10% | – | – | 3 7% | 2 5% | 1 2% | – | 4 10% |
Medullo-blastoma/ PNET | 146 (11.4) | 26 18% | 22 85% | 18 (69%) 1 (4%) | – | 1 4% | – 1 (4%) | – | 4 15% | – | – | – | 1 4% |
Ependymo-ma | 90 (15.7) | 22 24% | 12 55% | 16 73% | – | – | – | – | 2 10% | 2 10% | 1 5% | – | 1 5% |
Craniopharyngeoma | 81 (17.2) | 13 16% | 3 23% | 2 15% | – | 3 23% | – | 3 23% | – | 2 15% | 1 7.5% | – | 2 suddend 15% |
CNS other types | 255 (13.9) | 19 7.5% | 8 42% | 9 47% | 2 11% | – | – | 2 11% | 2 11% | 3 16% | – | 1 5% | – |
Neuroblas-toma stage 1–2 | 202 (14.6) | 2 1% | 1 50% | 1 50% | – | – | – | – | – | – | 1 50% | – | – |
Neuroblas-toma stage 3–4 | 179 (15.3) | 23 12,8% | 13 57% | 15 68% | – | – | – | 2 9% | 4 17% | 1 4% | – | – | 1 4% |
Wilms tumour | 343 (18.7) | 12 3,5% | 7 58% | 5 42% | 1 8% | – | – | – | 4 33% | – | – | 2 17% | – |
Softtissue sarcomas | 256 (17.3) | 20 7,8% | 13 65% | 14 70% | – | – | – | 1 5% | 4 20% | – | 1 5% | – | – |
Ewing sarcoma | 108 (9.8) | 20 18,5% | 17 85% | 14 74% | – | – | – | 2 11% | 3 16% | – | – | – | 1 5% |
Osteo- sarcoma | 160 (15.2) | 20 12,5% | 8 40% | 7 35% | – | – | 1 5% | 4 20% | 6 30% | – | 2 10% | – | – |
Retinoblas-toma | 127 (17.3) | 4 3,1% | 2 50% | – | – | – | – | – | 2 50% | 2* 50% | – | – | – |
Primary hepatic tumours | 50 (12.4) | 2 4% | 2 100% | 2 100% | – | – | – | – | – | – | – | – | – |
Carcinoma | 135 (10.7) | 8 6% | 5 63% | 5 63% | – | – | – | 1 12% | 2 25% | – | – | – | – |
Germcell tumours | 137 (16.3) | 8 6% | 3 38% | 3 38% | 1 12% | – | – | – | 2 25% | – | – | 2 25% | – |
Other tumours | 10 (10.7) | 1 10% | 1 100% | 1 100% | – | – | – | – | – | – | – | – | – |
All cases | 3,650 (16.6) | 301 8.2% | 161 53.5% | 158 52.5% | 10 3% | 11 4% | 6 2% | 25 8% | 47 16% | 12 4% | 9 3% | 7 2% | 16 5% |
